Titre : Communication autocrine

Communication autocrine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Controlled Substances
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Communication autocrine : Questions médicales les plus fréquentes", "headline": "Communication autocrine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Communication autocrine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-27", "dateModified": "2025-04-22", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Communication autocrine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Communication cellulaire", "url": "https://questionsmedicales.fr/mesh/D002450", "about": { "@type": "MedicalCondition", "name": "Communication cellulaire", "code": { "@type": "MedicalCode", "code": "D002450", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G04.085" } } }, "about": { "@type": "MedicalCondition", "name": "Communication autocrine", "alternateName": "Autocrine Communication", "code": { "@type": "MedicalCode", "code": "D019898", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Mei Chen", "url": "https://questionsmedicales.fr/author/Mei%20Chen", "affiliation": { "@type": "Organization", "name": "Department of Dermatology and the USC-Norris Comprehensive Cancer Center, University of Southern California Keck Medical Centre, Los Angeles, CA, 90033, USA." } }, { "@type": "Person", "name": "Hamideh P Fallah", "url": "https://questionsmedicales.fr/author/Hamideh%20P%20Fallah", "affiliation": { "@type": "Organization", "name": "Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, Alberta, T2N 1N4, Canada." } }, { "@type": "Person", "name": "Hamid R Habibi", "url": "https://questionsmedicales.fr/author/Hamid%20R%20Habibi", "affiliation": { "@type": "Organization", "name": "Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, Alberta, T2N 1N4, Canada. Electronic address: Habibi@ucalgary.ca." } }, { "@type": "Person", "name": "Michael Downes", "url": "https://questionsmedicales.fr/author/Michael%20Downes", "affiliation": { "@type": "Organization", "name": "Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037." } }, { "@type": "Person", "name": "Ronald M Evans", "url": "https://questionsmedicales.fr/author/Ronald%20M%20Evans", "affiliation": { "@type": "Organization", "name": "Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling.", "datePublished": "2022-08-17", "url": "https://questionsmedicales.fr/article/35987353", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.neuropharm.2022.109220" } }, { "@type": "ScholarlyArticle", "name": "Concordance between controlled substance receipt and post-mortem toxicology in opioid-detected overdose deaths: A statewide analysis.", "datePublished": "2023-01-30", "url": "https://questionsmedicales.fr/article/36738634", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.drugalcdep.2023.109788" } }, { "@type": "ScholarlyArticle", "name": "The impact of scheduling ketamine as an internationally controlled substance on anaesthesia care in Sub-Saharan Africa: a case study and key informant interviews.", "datePublished": "2024-05-07", "url": "https://questionsmedicales.fr/article/38715038", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12913-024-11040-w" } }, { "@type": "ScholarlyArticle", "name": "Impact of mandatory COVID-19 shelter-in-place order on controlled substance use among rural versus urban communities in the United States.", "datePublished": "2022-06-16", "url": "https://questionsmedicales.fr/article/35710976", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jrh.12688" } }, { "@type": "ScholarlyArticle", "name": "Cardiopulmonary and muscular effects of different doses of high-intensity physical training in substance use disorder patients: study protocol for a block allocated controlled endurance and strength training trial in an inpatient setting.", "datePublished": "2022-09-27", "url": "https://questionsmedicales.fr/article/36167363", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bmjopen-2022-061014" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes physiologiques cellulaires", "item": "https://questionsmedicales.fr/mesh/D002468" }, { "@type": "ListItem", "position": 3, "name": "Communication cellulaire", "item": "https://questionsmedicales.fr/mesh/D002450" }, { "@type": "ListItem", "position": 4, "name": "Communication autocrine", "item": "https://questionsmedicales.fr/mesh/D019898" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Communication autocrine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Communication autocrine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-14", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Communication autocrine", "description": "Comment diagnostiquer une communication autocrine ?\nQuels tests sont utilisés pour évaluer la communication autocrine ?\nY a-t-il des marqueurs spécifiques pour la communication autocrine ?\nLa communication autocrine est-elle visible par imagerie ?\nQuels sont les signes d'une dérégulation autocrine ?", "url": "https://questionsmedicales.fr/mesh/D019898?mesh_terms=Controlled+Substances&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Communication autocrine", "description": "Quels symptômes indiquent une communication autocrine anormale ?\nLa communication autocrine affecte-t-elle le métabolisme ?\nY a-t-il des symptômes spécifiques liés à l'autocrine dans le cancer ?\nComment la communication autocrine influence-t-elle l'immunité ?\nDes symptômes neurologiques peuvent-ils être liés à l'autocrine ?", "url": "https://questionsmedicales.fr/mesh/D019898?mesh_terms=Controlled+Substances&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Communication autocrine", "description": "Comment prévenir les dérégulations autocrines ?\nY a-t-il des mesures préventives spécifiques pour le cancer ?\nL'exercice physique aide-t-il à réguler l'autocrine ?\nLe stress influence-t-il la communication autocrine ?\nDes compléments alimentaires peuvent-ils aider ?", "url": "https://questionsmedicales.fr/mesh/D019898?mesh_terms=Controlled+Substances&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Communication autocrine", "description": "Quels traitements ciblent la communication autocrine ?\nLes médicaments peuvent-ils moduler la communication autocrine ?\nY a-t-il des traitements spécifiques pour le cancer liés à l'autocrine ?\nComment la thérapie génique influence-t-elle l'autocrine ?\nLes traitements hormonaux affectent-ils la communication autocrine ?", "url": "https://questionsmedicales.fr/mesh/D019898?mesh_terms=Controlled+Substances&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Communication autocrine", "description": "Quelles complications peuvent résulter d'une communication autocrine anormale ?\nLa communication autocrine peut-elle entraîner des troubles métaboliques ?\nY a-t-il des risques d'inflammation chronique ?\nComment la communication autocrine affecte-t-elle le cancer ?\nDes complications neurologiques sont-elles possibles ?", "url": "https://questionsmedicales.fr/mesh/D019898?mesh_terms=Controlled+Substances&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Communication autocrine", "description": "Quels sont les facteurs de risque de dérégulation autocrine ?\nL'alimentation influence-t-elle la communication autocrine ?\nLe stress est-il un facteur de risque ?\nY a-t-il des prédispositions génétiques ?\nL'exposition à des produits chimiques est-elle un risque ?", "url": "https://questionsmedicales.fr/mesh/D019898?mesh_terms=Controlled+Substances&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une communication autocrine ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests biologiques et des analyses de signalisation cellulaire." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer la communication autocrine ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de culture cellulaire et des dosages de cytokines peuvent être utilisés." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs spécifiques pour la communication autocrine ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des marqueurs comme les récepteurs de cytokines peuvent indiquer une communication autocrine." } }, { "@type": "Question", "name": "La communication autocrine est-elle visible par imagerie ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Elle n'est généralement pas visible par imagerie, mais des techniques avancées peuvent aider." } }, { "@type": "Question", "name": "Quels sont les signes d'une dérégulation autocrine ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des signes incluent une croissance cellulaire anormale ou une inflammation persistante." } }, { "@type": "Question", "name": "Quels symptômes indiquent une communication autocrine anormale ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes peuvent inclure des douleurs, des inflammations ou des tumeurs." } }, { "@type": "Question", "name": "La communication autocrine affecte-t-elle le métabolisme ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut influencer le métabolisme cellulaire et provoquer des déséquilibres." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques liés à l'autocrine dans le cancer ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme la fatigue et la perte de poids peuvent être présents." } }, { "@type": "Question", "name": "Comment la communication autocrine influence-t-elle l'immunité ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut moduler la réponse immunitaire, entraînant une inflammation ou une immunosuppression." } }, { "@type": "Question", "name": "Des symptômes neurologiques peuvent-ils être liés à l'autocrine ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles neurologiques peuvent survenir en raison de la signalisation autocrine." } }, { "@type": "Question", "name": "Comment prévenir les dérégulations autocrines ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et un mode de vie sain peuvent aider à prévenir ces dérégulations." } }, { "@type": "Question", "name": "Y a-t-il des mesures préventives spécifiques pour le cancer ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, éviter les carcinogènes et maintenir un poids santé sont des mesures préventives." } }, { "@type": "Question", "name": "L'exercice physique aide-t-il à réguler l'autocrine ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut moduler la signalisation autocrine et améliorer la santé cellulaire." } }, { "@type": "Question", "name": "Le stress influence-t-il la communication autocrine ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut perturber la communication autocrine et affecter la santé." } }, { "@type": "Question", "name": "Des compléments alimentaires peuvent-ils aider ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Certains compléments, comme les oméga-3, peuvent moduler la communication autocrine." } }, { "@type": "Question", "name": "Quels traitements ciblent la communication autocrine ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies ciblées et des inhibiteurs de signalisation peuvent être utilisés." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils moduler la communication autocrine ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent inhiber ou stimuler la signalisation autocrine." } }, { "@type": "Question", "name": "Y a-t-il des traitements spécifiques pour le cancer liés à l'autocrine ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements comme les anticorps monoclonaux ciblent souvent la communication autocrine dans le cancer." } }, { "@type": "Question", "name": "Comment la thérapie génique influence-t-elle l'autocrine ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique peut corriger des dérégulations dans la communication autocrine." } }, { "@type": "Question", "name": "Les traitements hormonaux affectent-ils la communication autocrine ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements hormonaux peuvent influencer la signalisation autocrine dans certaines pathologies." } }, { "@type": "Question", "name": "Quelles complications peuvent résulter d'une communication autocrine anormale ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des cancers, des maladies auto-immunes et des inflammations chroniques." } }, { "@type": "Question", "name": "La communication autocrine peut-elle entraîner des troubles métaboliques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une dérégulation peut provoquer des troubles métaboliques comme le diabète." } }, { "@type": "Question", "name": "Y a-t-il des risques d'inflammation chronique ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une communication autocrine anormale peut entraîner une inflammation chronique." } }, { "@type": "Question", "name": "Comment la communication autocrine affecte-t-elle le cancer ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut favoriser la croissance tumorale et la résistance aux traitements anticancéreux." } }, { "@type": "Question", "name": "Des complications neurologiques sont-elles possibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des dérégulations peuvent entraîner des troubles neurologiques et cognitifs." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque de dérégulation autocrine ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, l'obésité, le tabagisme et l'exposition à des toxines." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle la communication autocrine ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en sucres et graisses peut perturber la signalisation autocrine." } }, { "@type": "Question", "name": "Le stress est-il un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut augmenter le risque de dérégulation autocrine." } }, { "@type": "Question", "name": "Y a-t-il des prédispositions génétiques ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines mutations génétiques peuvent prédisposer à des dérégulations autocrines." } }, { "@type": "Question", "name": "L'exposition à des produits chimiques est-elle un risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des produits chimiques toxiques peut augmenter le risque de dérégulation." } } ] } ] }

Sources (10000 au total)

Concordance between controlled substance receipt and post-mortem toxicology in opioid-detected overdose deaths: A statewide analysis.

Opioid overdoses are a leading cause of preventable death in the United States. There is limited research linking decedents' receipt of controlled substances and presence of controlled substances on p... We linked data on opioid-detected deaths in Connecticut between May 3, 2016, and December 31, 2017 from the Office of the Chief Medical Examiner, Department of Consumer Protection, and Department of M... Our analysis included 1412 opioid-detected overdose deaths. 47 % received an opioid or benzodiazepine 90 days prior to death; 36 % received an opioid and 27 % received a benzodiazepine. Concordance be... Our results suggest medically supplied opioids and benzodiazepines potentially contributed to a substantial number, though minority, of opioid-detected deaths during the study period. Efforts to reduc...

The impact of scheduling ketamine as an internationally controlled substance on anaesthesia care in Sub-Saharan Africa: a case study and key informant interviews.

Access to anaesthesia and surgical care is a major problem for people living in Sub-Saharan Africa. In this region, ketamine is critical for the provision of anaesthesia care. However, efforts to cont... This research is a mixed-methods study, comprising of a cross-sectional survey at the hospital level in Rwanda, and key informant interviews with experts on anaesthesia care in Sub-Saharan Africa. Dat... The survey conducted in Rwanda found that availability of ketamine and propofol was comparable at around 80%, while thiopental and inhalational agents were available at only about half of the hospital... Ketamine is critical for the provision of anaesthesia care in Sub-Saharan Africa, and its scheduling would have a significantly negative impact on its availability for anaesthesia care....

Impact of mandatory COVID-19 shelter-in-place order on controlled substance use among rural versus urban communities in the United States.

Mandatory COVID-19 shelter-in-place (SIP) orders have been imposed to fight the pandemic. They may also have led to unintended consequences of increased use of controlled substances especially among r... Call counts received by the poison control centers between October 19, 2019 and July 6, 2020 due to exposure to controlled substance (methamphetamine, opioids, cocaine, benzodiazepines, and other narc... During the study period, 2,649 counties in the United States had mandatory SIP orders. The rate of calls reporting exposure to any of the aforementioned controlled substances among the rural counties ... The mandatory SIP orders may have had an unintended consequence of exacerbating the use of controlled substances at home in rural communities relative to urban communities....

Cardiopulmonary and muscular effects of different doses of high-intensity physical training in substance use disorder patients: study protocol for a block allocated controlled endurance and strength training trial in an inpatient setting.

Patients with substance use disorder (SUD) have high prevalence of lifestyle-related comorbidities. Physical exercise is known to yield substantial prophylactic impact on disease and premature mortali... This study will recruit 40 in-patients of mixed genders, aged 18-70 years. Participants will be block allocated to low-dose or high-dose training, encompassing 24 high-intensity interval and maximal s... This protocol is in accordance with the Standard Protocol Items: Recommendations for Interventional Trials statement. All participants will sign a written informed consent. The Regional Committee of M... NCT04065334....

Acute, chronic, and post-mortem toxicity: a review focused on three different classes of new psychoactive substances.

New psychoactive substances (NPS) are not controlled under the Single Convention on Narcotic Drugs of 1961 or the 1971 Convention, but they may pose a public health threat. Knowledge of the main prope... We carried out a literature review collecting information on the acute, chronic, and post-mortem toxicity of these classes of NSP. We searched info in five scientific databases considering works from ... Results have shown a general lack of studies in this field given that many NPS have not had their toxicity evaluated. We observed a significant difference in the volume of data concerning acute and ch... More in-depth information about the main threats involving NPS use are needed....

Does electronic prescribing of controlled substances deter controlled substance prescribing in emergency departments?

To examine the association between electronic prescribing of controlled substances (EPCS) and controlled substance prescription patterns in U.S. emergency departments (ED).... We conducted cross-sectional analysis at both the ED level and visit level, using the 2016-2017 National Hospital Ambulatory Medical Care Surveys.... The sample included 24,296 visits to 316 EDs, 45% of which utilized EPCS. Pain-related visits were associated with significantly higher odds of prescriptions for any controlled substances (OR = 1.52; ... While EPCS transmits prescriptions directly to pharmacies in order to reduce drug diversion problems, the results indicated no significant association between EPCS use and prescriptions for Schedule I... EPCS does not appear to deter Schedule II controlled substances prescription including opioids in an ED visit. It may facilitate any and Schedule III controlled substance prescriptions when pain was i...